Glaxo Fined $54.3 Million in `Pay-for-Delay' Antitrust Probe
- U.K. antitrust regulator says deals blocked generic drugs
- Generic drug makers are also fined for 2001-2004 deals
This article is for subscribers only.
GlaxoSmithKline Plc was fined 37.6 million pounds ($54.3 million) by the U.K.’s antitrust watchdog over pay-for-delay deals that held back sales of cheaper, generic versions of its anti-depressant Seroxat.
The London-based drugmaker colluded with other companies from 2001 to 2004 by agreeing to make payments “and other value transfers totaling over 50 million pounds to suppliers of generic versions of paroxetine,” the Competition and Markets Authority said in a statement Friday.